Table II.
Univariate analysis of the first therapeutic-target-achieving time and initial dosage, heart failure and liver function.
| Initial dosage (mg) | Heart failure | Liver function | |||||
|---|---|---|---|---|---|---|---|
| Group | 2.5 | 3 | 5 | No | Yes | Normal | Abnormal |
| I | 12 (10.81) | 41 (26.28) | 15 (41.67) | 54 (19.71) | 14 (50.00) | 52 (20.16) | 16 (36.36) |
| II | 27 (24.32) | 43 (27.56) | 10 (27.78) | 74 (27.01) | 6 (21.43) | 72 (27.91) | 8 (18.18) |
| III | 49 (44.14) | 51 (32.69) | 8 (22.22) | 102 (37.23) | 6 (21.43) | 90 (34.88) | 18 (40.91) |
| IV | 23 (20.72) | 21 (13.46) | 3 (8.33) | 44 (16.06) | 2 (7.14) | 44 (17.05) | 2 (4.55) |
| χ2/F | 21.943 | 15.301 | 9.971 | ||||
| P-value | 0.001a | <0.001b | 0.019c | ||||
Among groups, P<0.05 was considered significant. Data are presented as n (%).
a
P-value of first therapeutic-target-achieving (TTA) comparison among the 2.5, 3 and 5 mg group.
b
P-value of first TTA compared to the heart and no heart failure groups.
c
P-value of the first TTA compared between the normal liver and abnormal liver function groups. The χ2 test was used for statistical analysis.